Trial Profile
A phase I study of oral topotecan as a radiosensitizing agent in patients with rectal cancer
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Topotecan (Primary)
- Indications Rectal cancer
- Focus Adverse reactions
- Sponsors GSK
- 13 Jun 2007 Status changed from recruiting to discontinued
- 17 Oct 2005 New trial record.